Bristol and Merck both present impressive data at ASCO, but no clear-cut winner yet.
Biotech IPOs provide some powerful indications...
Sarepta's roller coaster ride is not finished yet.
RNAi is a new biotech technology investors need to watch.
An update on my prediction that Bristol-Myers Squibb will outperform in 2014.
An Early Look at Some 2014 Predictions of Bristol, Vertex, Sarepta and Innate Pharma.
Dissecting Bristol-Myers Squibb's 4th quarter earnings call.
Where does the biotech sector stand today?